The purpose of this study was to establish and characterize patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mice for utilization in antitumor drug discovery. A total of 96 esophageal squamous cell carcinoma (ESCC) tissues from Chinese patients were transplanted subcutaneously into immunodeficient mice. Histology, EGFR, K-ras, B-raf, and PIK3CA mutations, and HER2 gene amplifications were analyzed in both patient tumors and mouse xenograft tissues using immunohistochemistry, mutant-enriched liquid chip sequencing and fluorescence in situ hybridization assays, respectively. Furthermore, in vivo efficacy studies using five PDECX mice harboring a variety of genetic aberrations were performed using the chemotherapy agents 5-fluorouracil (5-FU) and cisplatin. Thirty-seven PDECX mouse models were successfully established in immunodeficient mice. Pathological analysis revealed similar histological architecture and degrees of differentiation between patient ESCC and xenografted tumors. No mutations were identified in EGFR, K-ras, and B-raf genes in either xenograft models or patient ESCC tissues. In contrast, PIK3CA gene mutations were detected in 12.5% (12/96) ESCC patients and 18.9% (7/37) PDECX models. Interestingly, patient ESCC tissues exhibiting HER2 overexpression or gene amplification were unable to survive in immunodeficient mice. Further analysis showed that PDECX models carrying HER2 2 þ expression had no response to 5-FU/cisplatin, compared with HER2-negative models. In conclusion, a panel of PDECX mouse models, which include PIK3CA mutant and HER2-positive models, was established and characterized thus mimicking the current clinical genetic setting of esophageal carcinoma. The sensitivity of HER2-negative ESCC models to chemotherapy supports stratification approaches in the treatment of esophageal carcinoma patients and warrants further investigation of the impact of PI3KCA on treatment response.
Esophageal squamous cell carcinoma (ESCC) is one of the most prevalent cancers worldwide and occurs at a relatively high frequency (450 per 100 000 population) in some areas of China. 1, 2 Furthermore, it has been suggested that ethnic factors can contribute to esophageal cancer susceptibility. 1 ESCC is a complex disease, the mortality rate associated with ESCC is similar to the incidence rate due to diagnosis at a generally advanced stage, its aggressive characteristics, and a paucity of effective treatment strategies. 3 In spite of its poor prognosis, however, ESCC has not been well studied to date.
Surgery remains one of the fundamental treatment strategies, however, the 5-year survival for nonmetastatic disease is 20-40%. 4 Patients with metastatic disease who are treated with palliative chemotherapy using a combination of 5-fluorouracil (5-FU) and cisplatin have a median survival of less than 1 year with response rates of 25-45% in phase II and III trials. 3, 5 Salvage options for patients with refractory ESCC are rare. 6 Recently, neoadjuvant treatment approaches using a combination of chemotherapy and radiotherapy have been performed on locally advanced EC, with some improvements observed in clinical trials. [7] [8] [9] Despite these limited improvements, the prognosis for these patients remains poor. 10 In addition, the trimodal therapeutic model (use of cetuximab in combination with definitive chemoradiotherapy) appeared to offer hope in a phase IB/II clinical trial, 11 but failed in a later phase IIB/III clinical trial. 12 Furthermore, the efficacy of new therapeutic drugs remains to be tested in ESCC as most of the previous trials have included predominantly esophageal adenocarcinoma patients. [13] [14] [15] [16] [17] [18] [19] Despite some successes in the treatment of cancers, 9 more novel rational therapies targeting specific cancer-related molecules are urgently needed. The increasing body of knowledge around molecular and genetic events involved in oncogenesis and tumor progression has led to the identification of new therapeutic targets and the synthesis of novel therapeutic agents. Animal models have been used in front-line preclinical studies for predicting the efficacy and possible toxicities of anticancer drugs in cancer patients. 20 Although the advent of cancer cell-line culture techniques fuelled an acceleration and expansion of cancer biology discovery that continues to this day, the harsh reality is that there is a high failure rate among new oncology agents when attempting to translate preclinical efficacy into clinical benefit. One of the most frequently cited reasons is the lack of preclinical models that recapitulate the heterogeneity of tumors in patients. 21, 22 Human tumor fragments obtained from patients and directly transplanted into immunodeficient mice, known as primary xenografts or tumor grafts, are one category of recognized models used as tools for preclinical assays. [23] [24] [25] [26] [27] [28] Although the methods have been established for decades, these preclinical models are only now being consistently characterized and applied to drug development in oncology. There is a strong evidence that a greater genetic divergence exists between a primary tumor and the corresponding cell line derived from that tumor, versus a direct xenograft. 22, 29 Future preclinical evaluation of these and other agents for ESCC requires the development of animal models of human ESCC. To obtain preclinical results with high predictive value for clinical trials, the choice of the tumor models on which new compounds and novel drug combinations are evaluated is critical.
In the present study, we used fresh patient ESCC tissues to establish patient-derived esophageal squamous cell carcinoma xenograft (PDECX) models in immunodeficient mice to support drug discovery and development.
MATERIALS AND METHODS Patients and Tissue Samples
From March to August 2010 with the assistance of the Department of Thorax Surgery, Zhongshan Hospital, 96 patient primary ESCC tissues without any preoperative treatment were obtained intraoperatively during esophagetomy resection at Zhongshan Hospital. None of the patients received any therapies before surgery. Prior written informed consent was provided from all patients and the study protocol received Ethics Board approval at Zhongshan Hospital, Fudan University. Where sufficient residual tumor tissue was available, histopathological examination and related analyses were performed. The tumor specimens were collected at surgery and divided into three parts for the following purposes: implantation into immunodeficient mice for xenograft model establishment, snap freezing in liquid nitrogen for DNA/RNA extraction, and fixed in 10% formalin buffer for 24 h and embedded into paraffin for immunohistochemical (IHC) analysis.
Clinical Data Collection
The diagnosis of ESCC was confirmed by histological analysis in all cases. Then, the following patient characteristics were collected for research study only, including: gender, age, tumor site (upper, middle, and lower of esophagus), histological grade, coagulative necrosis, nerve and vascular infiltration, mitotic index (number recorded as o50/10 HPF, or Z50/10 HPF), lymph node metastasis, and stage as previously reported. 4 Establishment of PDECX Mouse Models Eight-to ten-week-old female nude (nu/nu) and the severe combined immune-deficient (SCID) mice (Vital River, Beijing, China) were used for xenograft model generation in this study. All experiments with immunodeficient mice were performed in accordance with the guidelines approved by IACUC. The PDECX models were established with fresh patient ESCC tissues, surgically removed from ESCC patients, as described in a previous study. 30 In brief, surgically removed patient's ESCC tissues (F0 tissue) were cut into fragments of approximately 15 mm 3 in volume and implanted subcutaneously via Trocar needle into female SCID mice within 2 h after surgery. Patient tumor-implanted mice were observed daily until 90 days. Tumors were measured once a week by caliper when tumors started to grow up in mice. The B500 mm 3 xenografted ESCC tumors subsequently harvested from the mice were further implanted and expanded in nude mice. After three consecutive mouseto-mouse passages, the xenograft was considered to be stable and was characterized. The xenografted tumor specimens in each passage of tumor-bearing mice were harvested and divided into three parts for the following purposes. The first was implanted into immunodeficient mice for the next generation of the xenograft model. The second part was used for DNA/RNA extraction by snap freezing in liquid nitrogen. The third part was fixed in 10% formalin buffer for 24 h and embedded into paraffin for IHC analysis. Fresh tumor fragments at passages 3-5 were frozen with 20% FCS in liquid nitrogen for further model recovery and utilization for drug discovery.
H&E and IHC Staining
Tissues from all PDECX models and the corresponding ESCC patient tumors were harvested and fixed in 10% buffered formalin within 30 min after resection according to our previous study. Sections were stained with hematoxylin and eosin and reviewed by two pathologists to confirm the ESCC diagnosis. Dual cores from each tissue were made on tissue microarray (TMA) for IHC and fluorescence in situ hybridization analysis. For the IHC, all incubations were at room temperature and washes were performed with TBST. Antigen retrieval was performed in a pressure cooker at 110 1C for 5 min in retrieval buffer (S2367, DAKO). Endogenous peroxidase activity was blocked with 3% hydrogen peroxide (S2023, DAKO). Sections were then incubated with anti-HER2 antibody (HerceptestTM, DAKO) for 30 min. Immunocomplexes were detected by incubation with DAKO K5204 for 30 min and were visualized with diaminobenzidine (K3468, DAKO) for 10 min. For HER2-negative cases, the experiment was repeated on the whole section in order to exclude heterogeneity. The IHC scoring criteria on ESCC followed Hoffman's criteria on human gastric cancer: 31 no staining or o10% tumor cell-positive staining as 0/negative; faintly or barely perceptible staining on 410% tumor cell membrane as 1 þ ; weak to moderate positive staining on 410% tumor cells as 2 þ ; as tumor tissues on TMA mimic the biopsy samples, cohesive moderate to strong staining on the membranes were scored as 3 þ .
HER2 Fluorescence
In Situ Hybridization Assay TMA sections were dewaxed and dehydrated. Tissue pretreatment was performed according to the SpotLight Tissue pretreatment kit manual (Invitrogen, Cat #00-8401). After pretreatment, 10 ml HER2/CEP17 probes were applied onto each TMA slide, covered with coverslip and circled around the edge of coverslip with rubber cement (Mpbio, Cat #11FIXO0125). Sections together with probes were codenaturated at 75 1C for 4 min on OmniSlide In-Situ hybridization System, then incubated at 37 1C overnight. After codenaturation and incubation, probes were washed off sequentially with 0.3% NP40/1 Â SSC at 75.5 1C for 3 min, and 0.3% NP40/2 Â SSC at 75.5 1C for 2 min, 2 Â SSC at room temperature 2 min, two times, then dehydrated sequentially in 70, 85 and 100% ethanol, and air dried. Sections were mounted with 0.3 mg/ml DAPI mounting medium (diluted from Vector, Cat #H-1200), and stored at 4 1C to avoid light for at least 30 min before scoring.
In each case, 50 tumor nuclei were evaluated. Cases showing average gene copy number of HER2 46 or a gene/CEN17 fluorescence ratio Z2 were considered gene amplified. Amplification was also defined in cases where HER2 signals formed a tight gene cluster. The above criteria are based on Hoffmann's criteria 31 and related investigations. 32, 33 Gene Mutation Screening Formalin-fixed paraffin-embedded tumor blocks were reviewed for quality and tumor content. A single representative block, from either the patient primary tumor or the xenograft model, containing at least 70% of neoplastic cells, was selected for gene analysis. Genomic DNA was extracted using the QIAamp Mini kit (Qiagen) according to the manufacturer's instructions. Based on the prevalence of gene mutations and molecular segmentation in other tumor types (as well as our previously published data; Hou et al), 34 'hot spot' EGFR, K-ras, B-raf, and PIK3CA gene mutations were screened for using the mutant-enriched PCR method. 35 The method was performed by SurExam Bio-Tech Co. Ltd., Guangzhou Technology Innovation Base, Science City, Guangzhou, PRC. Positive results were further confirmed by PCR-direct sequencing. The primers for exon 9 of PIK3CA gene were 5 0 -GTCTTAGATTGGTTCTTTCCTG-3 0 for forward and 5 0 -GCATTTAATGTGCCAACTACC-3 0 for reverse, for exon 20 of PIK3CA gene were 5 0 -TTTGTCTACGA AAGCCTCTCTA-3 0 for forward and 5 0 -CCATCACTTTTT CCTTCTCCAT-3 0 for reverse.
Antitumor Efficacy of Cytotoxic Agents
For in vivo efficacy studies, xenograft tumor-bearing nude mice (tumor volumes of 150-250 mm 3 ) were sorted randomly and assigned to treatment groups (eight animals per group) or the vehicle control. The treatment groups received the chemotherapy drugs 5-FU/cisplatin (5-FU at 10 mg/kg/qd for 5 days a week intraperitoneally, and cisplatin at 5 mg/kg/ qd/once a week on the first day of the week, intravenously). Subcutaneous xenografted tumors in nude mice and mice body weight were measured twice a week. Tumor volumes were calculated by measuring two perpendicular diameters with calipers. Tumor volumes (V) were calculated by using the formula: V ¼ (length Â [width] 2 )/2. Percentage tumor growth inhibition (%TGI) was calculated using the formula: %TGI ¼ [1-(change of tumor volume in treatment group/change of tumor volume in control group)] Â 100 and was used for the evaluation of antitumor efficacy. Four stratification groups were defined based on criteria in previous publications: 24 (a) high responders, in which the treatment induced complete regressions (the established tumors being no longer palpable after treatment); (b) moderate responders, in which TGI was superior to 50%; (c) low responders, with TGI between 40 and 50%; and (d) the non-responders, in which the growth parameters were not significantly altered by the treatment.
Statistical Analysis
A w 2 test was used for univariate analyses, cross-tabulations with qualitative variables were analyzed with the Fisher's exact, with a P value less than 0.05 recorded as significant in clinical data analysis. To evaluate statistical significance in our antitumor efficacy studies, the Student's t-test was used to compare TGI in treatment groups to the control group. Statistical tests were two sided, with Po0.05 considered significant. 30 Examination of autopsies in ESCC-bearing mice from these xenograft mouse models at 2-3 months post-implantation revealed no evidence of metastases in the brain, lung, liver, or kidney. All established PDECX models could be recovered in mice after freeze/thawing of xenograft tumor fragments using liquid nitrogen (data not shown). Pathology assessment by H&E staining and analysis by pathologist revealed similar morphologies in PDECX tissues compared with that of the corresponding patient primary ESCC tissues in most cases (Figure 2a) .
Analysis of Potential Factors Affecting PDECX Model Establishment Success
Results of our correlation analyses between the success rates of PDECX model establishment and patient clinical parameters are listed in Compared with HER2 as a potential negative factor, PIK3CA mutation represents an unlikely factor in the successful establishment of PDECX mouse models (Table 1) . A total of 41.6% (5/12) of patient ESCC tissues harboring PIK3CA mutation grew up in immunodeficient mice ( Table 1) .
Characterization of PDECX Mouse Models
In order to characterize our established PDECX mouse models at both gene and protein levels, we screened for the major known genetic aberrations in esophageal carcinoma, both in model tissues and patient tumors, and performed IHC analysis. The list included mutations in PIK3CA, EGFR, K-ras, B-raf, and expression of HER2 protein in our 37 established PDECX models and the corresponding patient ESCC tissues. HER2 positivity (IHC score 1 þ , 2 þ or 3 þ ) was identified in 24.3% (9/37) of patient ESCC samples and 32.4% (12/37) of PDECX models. A total of 76% (28/37) of PDECX models showed consistent HER2 expression (positive or negative) compared with the corresponding patient ESCC tissues (Table 2 and Figure 2b) .
Gene mutations within EGFR (exons 18, 19, 20, 21), K-ras (exons 2 and 3), B-raf (exons 11 and 15), and PIK3CA (exons 9 and 20) were screened for within all 37 established PDECX model and patient ESCC tissues. Interestingly, no mutations were detected in EGFR, K-ras, or B-raf in any of the samples. PIK3CA mutation, however, was identified in 13.5% (5/37) of patient ESCC tissues (Figure 3 ) and 18.9% (7/37) of PDECX Figure 1 Success rates of PDECX model development at different passages.
Establishment of patient-derived ESCC xenografts J Zhang et al models. A total of 71% (5/7) of PDECX models showed consistent PIK3CA mutation when compared with the corresponding patient ESCC tissues. Interestingly, PIK3CA mutation in two additional PDECX models was not detected in the corresponding patient ESCC tissues.
PDECX Chemotherapy Anti-Tumor Efficacy Studies
To evaluate whether our PDECX mouse models responded to treatment with standard ESCC antitumor drugs, five available PDECX models were treated with the clinically used cytotoxic agents, 5-FU and cisplatin (Figure 4 ). Our data demonstrated that two PDECX models with genetic aberrations (HER2 IHC 2 þ in EC044; HER2 IHC 2 þ and PI3KCA mutation in EC039) had no significant response to cytotoxic agents (P40.05). Interestingly, however, three PDECX mouse models with HER2 negativity and wild-type PIK3CA were sensitive to 5-FU/cisplatin (49% TGI in EC004, Po0.05; 47% TGI in EC016, Po0.05; and 84% TGI in EC054, Po0.001). EC004 and EC016 were categorized as low responders, whereas EC054 was a moderate responder based on predefined response criteria. 24 
Wt, wild type.
Establishment of patient-derived ESCC xenografts J Zhang et al architecture. 25, 36 Development of esophageal animal xenograft models has been especially difficult but some success has been achieved, 37 either by the inoculation of EC cell lines into immunodeficient rodents (mice and rats) or rabbits. 15, [38] [39] [40] [41] Unfortunately, again, however, these cell lines also suffer from the same issues of long in vitro culture times and loss of original tumor characteristics. Another problem faced by the field of esophageal oncology research is that most of the commercially available EC cell lines were originally derived from esophageal adenocarcinoma, 15 45 the majority of PDECX models were of adenocarcinoma origin. Therefore, our present study aimed to establish a panel of Chinese patient-derived ESCC xenograft mouse models, harboring a variety of genetic aberrations and thereby constituting a pharmacologic platform for targeted drug efficacy evaluation.
In our study, a total of 37 viable and recoverable PDECX mouse models were established by implanting 96 fresh Chinese ESCC tissues into immunodeficient mice. Our successful engraftment rate of 38.5% was in the range of engraftment rates observed in similar patient-derived xenograft mouse model studies. 28, [46] [47] [48] [49] Correlative analysis between patient clinical characteristics and PDECX model establishment success rates demonstrated no statistically significant factors, but did, however, show potential negative trends associated with nerve invasion status and HER2 amplification or overexpression.
Based on published molecular analyses of the esophageal genetic landscape, together with our own published data (Hou et al, Boland and Burtness), 34, 50 we chose to focus on EGFR, KRas, BRaf, HER2, and PIK3CA. HER2 amplification and protein overexpression have been observed in ESCC and many other tumor types 33, 51 and often associates with poor prognosis. 31, [52] [53] [54] We identified 4.2% (5/96) of patient ESCC tissues showing overexpression or amplification of the HER2 gene, which was lower than previous reports. 33 Unexpectedly, patient ESCC tissues with HER2 gene amplification or overexpression (HER2 IHC 3 þ ) were unable to form stable PDECX models in immunodeficient mice. The majority of the failures (3/5) occurred in generation 1 (F1), whereas two models survived in the first generation and then failed in the second generation. These data are consistent with published observations of breast cancer xenograft development, where the establishment of patient-derived xenograft mouse models harboring HER2 amplification is rare. 24 Unfortunately, the underlying mechanism of how HER2 amplification or overexpression could contribute to model failure is currently unclear. We also acknowledge that the relatively low incidence of HER2 gene amplification or overexpression in this data set (4.2%) could likely introduce some bias in our statistical analyses.
In contrast to the negative impact of HER2 gene amplification on successful PDECX model establishment, PIK3CA gene mutation had no apparent impact. In all, 41.6% (5/12) of patient ESCC tissues harboring PIK3CA mutation grew up Figure 3 PIK3CA mutation in patient ESCC and the corresponding PDECX models. EC001 harbors a wild-type PIK3CA gene in primary tissue and xenografted model, EC039 contains a codon 542 GAA4AAA mutation, and EC058 has a codon 545 GAG4AAG mutation in exon 9 of the PIK3CA gene in both primary and xenografted tissues, EC074 has acquired a codon 542 GAA4AAA mutation as well as a codon 545 GAG4AAG mutation in xenografted tissue, EC104 acquired a codon 542 GAA4AAA mutation in xenografted tissue.
Establishment of patient-derived ESCC xenografts
J Zhang et al in immunodeficient mice, similar to the overall success rate (38.5%) of model establishment in this study. Interestingly, two additional PDECX models were identified as PIK3CA mutant, whereas the corresponding patient ESCC tissues were identified as PIK3CA wild type. We also observed that a further two PDECX models lost HER2 expression (from IHC 2 þ ) in the corresponding patient ESCC tissues to negative (IHC 0) in the PDECX models. Contrasting with this, three PDECX models showed HER2 2 þ expression but the HER2 positivity was not detected in the corresponding patient ESCC tissues. Multiple repeat experiments were performed to exclude technical error as a possible explanation for this result and the authors suggest tumor heterogeneity as a likely cause. Indeed, the location of the tissues used to establish the PDECX mouse models was different to that used to prepare formalin-fixed paraffin-embedded sections and perform genetic analysis. Another possibility may be clone enrichment or disappearance of human genetic aberrations within the mouse environment, however, this is speculation and is the subject of ongoing investigations. Taken together, these findings highlight the necessity for thorough characterization of patient-derived xenograft models before drug testing in preclinical drug discovery and development. In our previously published study, 30 Trastuzumab induced complete tumor regressions in PDECX mouse models with HER2 positivity (IHC 2 þ ), but was inefficacious in models harboring either PIK3CA mutation or combined HER2 IHC 2 þ positivity and PIK3CA mutation. In the present study, we extended these findings to demonstrate that PDECX models with HER2 negativity and wild-type PIK3CA were more sensitive to chemotherapy using 5-FU and cisplatin than PDECX models harboring genetic aberrations in HER2 or PIK3CA mutation.
In summary, a panel of PDECX mouse models, which included PIK3CA mutant and HER2-positive models, was established and characterized, thus mimicking the current clinical genetic setting of esophageal carcinoma. The sensitivity of HER2-negative ESCC models to chemotherapy supports stratification approaches in the treatment of esophageal carcinoma patients and warrants further investigation of the impact of PI3KCA on treatment response. 
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